Professor Colin Marschner

Professor
Medicine, Sydney Medical School
NHMRC Clinical Trials Centre

Telephone +61 2 9850 8557

Map

Research interests

Ian Marschner has over 20 years experience in biostatistics. He has worked on large scale clinical trials in a range of disease areas, particularly cardiovascular medicine. He also works on the development of new biostatistical methodology with applications in health and medical research, particularly clinical trials and clinical epidemiology.

Selected grants

2013

  • Advancing the evidence base for care and policy in priority health areas; Simes R, Keech A, Gebski V, Stockler M, Caterson I, Colagiuri S, Schofield D, Marschner C; National Health and Medical Research Council (NHMRC)/Program Grants.

2003

  • Advances in clinical trials research and evidence-based decision making; Marschner C, Stockler M, Keech A, Simes R, Gebski V; National Health and Medical Research Council (NHMRC)/Program Grants.

2002

  • Applied statistics; National Health and Medical Research Council (NHMRC)/Established Career Fellowships.

Selected publications

Download citations: PDF RTF Endnote

Book Chapters

  • Keech, A., Gebski, V., Marschner, C. (2007). Specifying objectives and outcomes for clinical trials. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 21-26). Sydney: AMPCo.

Journals

  • White, H., Simes, R., Stewart, R., Blankenberg, S., Barnes, E., Marschner, C., Thompson, P., West, M., Zeller, T., Colquhoun, D., Keech, A., Sullivan, D., et al (2013). Changes in lipoprotein-associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease study. Journal of the American Heart Association, 2(5), 1-12. [More Information]
  • Schou, I., Marschner, C. (2013). Meta-analysis of clinical trials with early stopping: an investigation of potential bias. Statistics in Medicine, 32(28), 4859-4874. [More Information]
  • Lee, C., Marschner, C., Simes, R., Voysey, M., Egleston, B., Hudes, G., de Souza, P. (2012). Increase in Cholesterol PredictsSsurvival Advantage in Renal Cell Carcinoma Patients Treated with Temsirolimus. Clinical Cancer Research, 18(11), 3188-3196. [More Information]
  • Marschner, C., Gillet, A. (2012). Relative risk regression: reliable and flexible methods for log-binomial models. Biostatistics, 13(1), 179-192. [More Information]
  • Marschner, C., Gillet, A., O'Connell, R. (2012). Stratified additive Poisson models: Computational methods and applications in clinical epidemiology. Computational Statistics and Data Analysis, 56(5), 1115-1130. [More Information]
  • Delahoy, P., Thompson, S., Marschner, I. (2010). Pregabalin versus gabapentin in partial epilepsy: a meta-analysis of dose-response relationships. BMC Neurology, 10(Article number 104), 1-11. [More Information]
  • Marschner, I. (2010). Regional differences in multinational clinical trials: anticipating chance variation. Clinical Trials, 7(2), 147-156. [More Information]
  • Cui, J., Forbes, A., Kirby, A., Marschner, C., Simes, R., Hunt, D., West, M., Tonkin, A. (2010). Semi-parametric risk prediction models for recurrent cardiovascular events in the LIPID study. BMC Medical Research Methodology, 10(27), 27-1-27-9. [More Information]
  • Simes, R., O'Connell, R., Aylward, P., Varshavsky, S., Diaz, R., Wilcox, R., Armstrong, P., Granger, C., French, J., Van de Werf, F., Marschner, C., et al (2010). Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy: Lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial. American Heart Journal, 159(6), 988-997. [More Information]
  • Cui, J., Forbes, A., Kirby, A., Marschner, C., Simes, R., West, M., Tonkin, A. (2008). Parametric conditional frailty models for recurrent cardiovascular events in the lipid study. Clinical Trials, 5(6), 565-574. [More Information]
  • Marschner, C., Simes, R., Keech, A. (2007). Biases in the Identification of Risk Factor Thresholds and J-Curves. American Journal of Epidemiology, 166(7), 824-831. [More Information]
  • Colquhoun, D., Keech, A., Hunt, D., Marschner, C., Simes, R., Glasziou, P., White, H., Barter, P., Tonkin, A. (2004). Effects Of Pravastatin On Coronary Events In 2073 Patients With Low Levels Of Both Low-Density Lipoprotein Cholesterol And High-Density Lipoprotein Cholesterol: Results From The Lipid Study. European Heart Journal, 25(9), 771-777. [More Information]
  • Marschner, C., Emberson, J., Irwig, L., Walter, S. (2004). The Number Needed To Treat (Nnt) Can Be Adjusted For Bias When The Outcome Is Measured With Error. Journal of Clinical Epidemiology, 57(12), 1244-1242. [More Information]
  • Galbraith, S., Marschner, C. (2002). Guidelines for the design of clinical trials with longitudinal outcomes. Contemporary Clinical Trials, 23(3), 257-273.
  • Simes, R., Marschner, C., Hunt, D., Sullivan, D., Colquhoun, D., Hague, W., Stewart, R., Keech, A., Thompson, P., White, H., et al (2002). Relationship between lipid levels and clinical outcomes in the long-term intervention with pravastatin in ischemic disease (LIPID) trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation, 105(10), 1162-1169.
  • Gebski, V., Marschner, C., Keech, A. (2002). Specifying objectives and outcomes for clinical trials. Medical Journal of Australia, 176(10), 491-492.
  • Marschner, C., Becker, N. (2001). Advances in medical statistics arising from the AIDS epidemic. Statistical Methods in Medical Research, 10, 117-140.
  • Marschner, C., Becker,, S. (2001). Interim monitoring of clinical trials based on long-term binary endpoints. Statistics in Medicine, 20, 177-192.
  • Marschner, C., Simes, R., Colquhoun, D., Glasziou, P., Harris, P., Singh, B., Friedlander, D., White, H., Thompson, P., Tonkin, A. (2001). Long-term risk stratification for survivors of acute coronary syndromes. Journal of the American College of Cardiology, 38(1), 56-63.
  • Marschner, C. (2001). On stochasitic versions of the EM algorithm. Biometrika, 88(1), 281-286.

2013

  • White, H., Simes, R., Stewart, R., Blankenberg, S., Barnes, E., Marschner, C., Thompson, P., West, M., Zeller, T., Colquhoun, D., Keech, A., Sullivan, D., et al (2013). Changes in lipoprotein-associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease study. Journal of the American Heart Association, 2(5), 1-12. [More Information]
  • Schou, I., Marschner, C. (2013). Meta-analysis of clinical trials with early stopping: an investigation of potential bias. Statistics in Medicine, 32(28), 4859-4874. [More Information]

2012

  • Lee, C., Marschner, C., Simes, R., Voysey, M., Egleston, B., Hudes, G., de Souza, P. (2012). Increase in Cholesterol PredictsSsurvival Advantage in Renal Cell Carcinoma Patients Treated with Temsirolimus. Clinical Cancer Research, 18(11), 3188-3196. [More Information]
  • Marschner, C., Gillet, A. (2012). Relative risk regression: reliable and flexible methods for log-binomial models. Biostatistics, 13(1), 179-192. [More Information]
  • Marschner, C., Gillet, A., O'Connell, R. (2012). Stratified additive Poisson models: Computational methods and applications in clinical epidemiology. Computational Statistics and Data Analysis, 56(5), 1115-1130. [More Information]

2010

  • Delahoy, P., Thompson, S., Marschner, I. (2010). Pregabalin versus gabapentin in partial epilepsy: a meta-analysis of dose-response relationships. BMC Neurology, 10(Article number 104), 1-11. [More Information]
  • Marschner, I. (2010). Regional differences in multinational clinical trials: anticipating chance variation. Clinical Trials, 7(2), 147-156. [More Information]
  • Cui, J., Forbes, A., Kirby, A., Marschner, C., Simes, R., Hunt, D., West, M., Tonkin, A. (2010). Semi-parametric risk prediction models for recurrent cardiovascular events in the LIPID study. BMC Medical Research Methodology, 10(27), 27-1-27-9. [More Information]
  • Simes, R., O'Connell, R., Aylward, P., Varshavsky, S., Diaz, R., Wilcox, R., Armstrong, P., Granger, C., French, J., Van de Werf, F., Marschner, C., et al (2010). Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy: Lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial. American Heart Journal, 159(6), 988-997. [More Information]

2008

  • Cui, J., Forbes, A., Kirby, A., Marschner, C., Simes, R., West, M., Tonkin, A. (2008). Parametric conditional frailty models for recurrent cardiovascular events in the lipid study. Clinical Trials, 5(6), 565-574. [More Information]

2007

  • Marschner, C., Simes, R., Keech, A. (2007). Biases in the Identification of Risk Factor Thresholds and J-Curves. American Journal of Epidemiology, 166(7), 824-831. [More Information]
  • Keech, A., Gebski, V., Marschner, C. (2007). Specifying objectives and outcomes for clinical trials. In Anthony Keech, Val Gebski, Rhana Pike (Eds.), Interpreting and reporting clinical trials: a guide to the CONSORT statement and the principles of randomised controlled trials, (pp. 21-26). Sydney: AMPCo.

2004

  • Colquhoun, D., Keech, A., Hunt, D., Marschner, C., Simes, R., Glasziou, P., White, H., Barter, P., Tonkin, A. (2004). Effects Of Pravastatin On Coronary Events In 2073 Patients With Low Levels Of Both Low-Density Lipoprotein Cholesterol And High-Density Lipoprotein Cholesterol: Results From The Lipid Study. European Heart Journal, 25(9), 771-777. [More Information]
  • Marschner, C., Emberson, J., Irwig, L., Walter, S. (2004). The Number Needed To Treat (Nnt) Can Be Adjusted For Bias When The Outcome Is Measured With Error. Journal of Clinical Epidemiology, 57(12), 1244-1242. [More Information]

2002

  • Galbraith, S., Marschner, C. (2002). Guidelines for the design of clinical trials with longitudinal outcomes. Contemporary Clinical Trials, 23(3), 257-273.
  • Simes, R., Marschner, C., Hunt, D., Sullivan, D., Colquhoun, D., Hague, W., Stewart, R., Keech, A., Thompson, P., White, H., et al (2002). Relationship between lipid levels and clinical outcomes in the long-term intervention with pravastatin in ischemic disease (LIPID) trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation, 105(10), 1162-1169.
  • Gebski, V., Marschner, C., Keech, A. (2002). Specifying objectives and outcomes for clinical trials. Medical Journal of Australia, 176(10), 491-492.

2001

  • Marschner, C., Becker, N. (2001). Advances in medical statistics arising from the AIDS epidemic. Statistical Methods in Medical Research, 10, 117-140.
  • Marschner, C., Becker,, S. (2001). Interim monitoring of clinical trials based on long-term binary endpoints. Statistics in Medicine, 20, 177-192.
  • Marschner, C., Simes, R., Colquhoun, D., Glasziou, P., Harris, P., Singh, B., Friedlander, D., White, H., Thompson, P., Tonkin, A. (2001). Long-term risk stratification for survivors of acute coronary syndromes. Journal of the American College of Cardiology, 38(1), 56-63.
  • Marschner, C. (2001). On stochasitic versions of the EM algorithm. Biometrika, 88(1), 281-286.

To update your profile click here. For support on your academic profile contact .